On Friday, Shares of AEterna Zentaris Inc. (USA)(NASDAQ:AEZS), saw its price movement on above normal volume, as 54.44M shares changed hands when compared with its average daily volume of 34.20M shares. The stock is down -17.35% to $.0562. The stock, as of previous close, has shown weekly downbeat performance of -36.5% which was maintained at -91.22% in this year. During last trade, the stock has moved down across its SMA 200 of $0.27
Aeterna Zentaris Inc. (AEZS) (AEZ.TO) declared that it has convened a special meeting of shareholders to be held on Monday, November 16, 2015 , at 9:30 a.m. (Eastern time) for shareholders of record on October 14, 2015 to consider a special resolution authorizing the consolidation of the issued and outstanding common shares of the Corporation at a consolidation ratio of between 8-for-1 and 100-for-1 and that the Notice of Special Meeting of Shareholders and Management Information Circular have been mailed to shareholders.
As of the record date for the Meeting of October 14, 2015 , there were 544,179,214 issued and outstanding Common Shares and approximately 5.3 million issued and outstanding Series B Share Purchase Warrants, representing approximately 17.7% of the number originally issued.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The company’s product pipeline includes MACRILEN, which completed the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer
The most recent price of PDL BioPharma Inc(NASDAQ:PDLI), is now at a discount to the 12-month high of $8.60 hit on Oct 24, 2014. The last price is at a premium to the 52-week low of $4.40 suffered on Oct 16, 2015. The stock, as of previous close, has shown weekly downbeat performance of -12.6% which was maintained at -40.6% in this year.
PDL BioPharma, Inc. manages a portfolio of patents and royalty assets in the United States and Europe. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
